ClearCell FX12 System

Biolidics partners Japan's Sysmex Corp for cancer-related R&D

SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tumour cells.

See: Biolidics selling 27.5 mil new shares at 28 cents each in conjunction with Catalist listing

Be informed of the stories that matter

Subscribe

Be informed of the stories that matter